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Abstract 40 
Hepatokines are liver-secreted proteins with potential to influence glucose regulation and 41 
other metabolic parameters. This study investigated differences in adiposity status on five 42 
novel hepatokines and characterised their response to acute moderate-intensity exercise in 43 
groups of normal weight and overweight/obese men.  44 
Twenty-two men were recruited into normal weight and overweight/obese groups (BMI: 18.5 45 
to 24.9 and 25.0 to 34.9 kg∙m-2). Each completed two experimental trials, exercise and control. 46 
During exercise trials, participants performed 60 min of moderate-intensity treadmill exercise 47 
(~60% V̇O2 peak) and then rested for 6 h. Participants rested throughout control trials. 48 
Circulating fibroblast growth factor-21 (FGF21), follistatin, leukocyte cell-derived 49 
chemotaxin 2 (LECT2), fetuin-A and selenoprotein-P (SeP) were measured throughout.  50 
Fasted (resting) FGF21 and LECT2 were higher in overweight/obese individuals (129% and 51 
55%; P ≤ 0.01) and correlated with indices of adiposity and insulin resistance; whereas 52 
circulating follistatin was lower in overweight/obese individuals throughout trial days (17%, 53 
P < 0.05). In both groups, circulating concentrations of FGF21 and follistatin were transiently 54 
elevated after exercise for up to 6 h (P ≤ 0.02). Circulating fetuin-A and SeP were no 55 
different between groups (P ≥ 0.19) and, along with LECT2, were unaffected by exercise (P 56 
≥ 0.06). 57 
These findings show that increased adiposity is associated with a modified hepatokine profile, 58 
which may represent a novel mechanism linking excess adiposity to metabolic health. 59 
Furthermore, acute perturbations in circulating FGF21 and follistatin after exercise may 60 
contribute to the health benefits of an active lifestyle. 61 
Key words: physical activity, insulin resistance, obesity, liver, organokines 62 
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Introduction 63 
Recent work characterising the hepatic proteome has identified 168 proteins which can be 64 
secreted and potentially exert endocrine-like effects in distal sites (Meex et al. 2015). A 65 
number of these ‘hepatokines’ are associated with measures of adiposity (Chen et al. 2011, 66 
Xu et al. 2011, Yang et al. 2011, Lan et al. 2014) and have been shown to exert metabolic 67 
effects within various central and peripheral tissues (Misu et al. 2010, Camporez et al. 2013, 68 
Malin et al. 2013, Lan et al. 2014, Hansen et al. 2016b). Together, this evidence has 69 
prompted suggestions that hepatokines represent a potential mechanism linking adiposity and 70 
metabolic health and may be novel therapeutic targets to combat obesity-related insulin 71 
resistance and associated metabolic disease. 72 
 73 
To date, much of the research concerning hepatokine function and metabolism has focused on 74 
their direct influence on tissue-specific insulin sensitivity and systemic glucose metabolism. 75 
The most frequently studied, fibroblast growth factor-21 (FGF21), has been shown to 76 
improve glucose metabolism in the liver, skeletal muscle and adipose tissue (Camporez et al. 77 
2013); whilst follistatin may promote pancreatic beta cell survival and suppress circulating 78 
glucagon (Hansen et al. 2016b). Other hepatokines may act to promote insulin resistance. For 79 
example, within skeletal muscle, leukocyte cell-derived chemotaxin 2 (LECT2) (Lan et al. 80 
2014), selenoprotein-P (SeP) (Misu et al. 2010) and fetuin-A (Malin et al. 2013) have each 81 
been shown to directly interfere with distinct aspects of glucose metabolism. Observational 82 
evidence in humans has identified associations between these hepatokines and adiposity, 83 
insulin resistance, ectopic lipid and the metabolic syndrome (Zhang et al. 2008, Li et al. 2010, 84 
Chen et al. 2011, Xu et al. 2011, Yang et al. 2011, Choi et al. 2013, Hansen et al. 2013, 85 
Okumura et al. 2013, Lan et al. 2014). However, human experimental research is now 86 
required to scrutinise the pathophysiological relevance of these novel proteins in vivo.  87 
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Current evidence demonstrates that exercise training reduces circulating levels of fetuin-A
 88 
and FGF21, and responses correlate with improvements in insulin sensitivity and intrahepatic 89 
fat (Malin et al. 2013, 2014, Taniguchi et al. 2016). Given that single bouts of exercise 90 
transiently enhance insulin sensitivity (Sylow et al. 2017), a handful of studies have also 91 
investigated the acute influence of exercise on circulating hepatokines, speculating that 92 
modulation of the hepatokine profile may be implicated in the benefits induced. This 93 
hypothesis is strengthened by the knowledge that exercise acutely increases circulating non-94 
esterified fatty acids (NEFA) and glucagon, and activates hepatic AMP-activated protein 95 
kinase (AMPK) (Camacho et al. 2006, Hansen et al. 2016a). Each of these have been 96 
implicated in the regulation of at least one of the hepatokines outlined above (Jung et al. 2013, 97 
Lan et al. 2014, Trepanowski et al. 2014, Hansen et al. 2016a). Whilst, these studies remain 98 
limited in number, the available evidence shows that moderate- to high-intensity aerobic 99 
exercise acutely increases circulating levels of FGF21 and follistatin (Slusher et al. 2015, 100 
Hansen et al. 2016a, 2016b), but responses may differ between normal weight and obese 101 
individuals, and between individuals with normal and dysregulated glucose metabolism 102 
(Slusher et al. 2015, Hansen et al. 2016a). Additional work is required to determine whether 103 
the FGF21 and follistatin responses to acute exercise differ between normal weight and 104 
overweight/obese individuals who are free of diagnosed metabolic disease, and whether 105 
similar responses occur in other relevant hepatokines.  106 
 107 
The purpose of this study was two-fold. Firstly, we sought to investigate differences in 108 
adiposity status on FGF21, follistatin, LECT2, SeP and fetuin-A in normal weight and 109 
overweight/obese men. Secondly, we characterised the effect of an acute bout of moderate-110 
intensity exercise on circulating concentrations of these hepatokines in order to explore their 111 
potential role as mediators of exercise-induced improvements in glycaemic control and other 112 
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metabolic parameters. We hypothesised that overweight/obese individuals would have 113 
elevated circulating concentrations of hepatokines at rest and that an acute bout of moderate-114 
intensity exercise would beneficially alter circulating hepatokine profiles; by reducing 115 
LECT2, SeP, and fetuin A, whilst increasing FGF21 and follistatin. 116 
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Materials and methods 117 
Ethical approval and participant recruitment 118 
After receiving approval from the East Midlands NHS Research Ethics committee 119 
(13/EM/0290), 22 non-smoking men were recruited equally into normal weight and 120 
overweight/obese groups (BMI: 18.5 to 24.9 and 25.0 to 34.9 kg∙m-2, respectively); providing 121 
written, informed consent to participate. This sample size was chosen based on previous 122 
studies that documented significant changes in hepatokines (FGF21 and follistatin) in 123 
response to acute exercise; as well as differences between participant groups (normal weight 124 
vs. obese and normal vs. impaired glucose regulation) (Slusher et al. 2015, Hansen et al. 125 
2016a, 2016b). Participants in the current study were free of diagnosed chronic disease and 126 
were not taking medications known to affect glucose or lipid metabolism, or blood pressure. 127 
Participants were also ‘inactive’ or ‘moderately active’ according to the International 128 
Physical Activity Questionnaire (www.ipaq.ki.se [accessed 03/01/2017]) and were weight 129 
stable in the three months prior to enrolment (< 2 kg self-reported weight change). 130 
 131 
Participant pre-assessment 132 
During a pre-assessment visit, participants were screened to determine eligibility and 133 
suitability for exercise testing. Participants underwent full medical evaluation, including 134 
assessment of cardiovascular disease risk, fasted capillary blood glucose and completion of 135 
the Physical Activity Readiness Questionnaire (www.csep.ca/en/publications [accessed 136 
03/01/2017]). Participants were excluded if blood pressure was greater then 160/100 mmHg, 137 
whilst resting and exercise electrocardiograms were performed to confirm the absence of 138 
established cardiac arrhythmias. Body fat was assessed using bioelectrical impedance 139 
analysis (BC-418, TANITA Europe BV, Amsterdam, The Netherlands) under standardised 140 
conditions and waist circumference was measured at the level of the umbilicus. 141 
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 142 
On a separate occasion, participants completed a 16-min, progressive sub-maximal exercise 143 
test on a motorised treadmill (Excite Med, Technogym, Italy), which was subsequently 144 
followed by a ramped peak oxygen uptake test. Expired air was collected continuously 145 
throughout both tests for quantification of oxygen consumption (V̇O2) and carbon dioxide 146 
production (V̇CO2) using breath-by-breath indirect calorimetry (Metalyser 3B, Cortex, 147 
Germany). Peak oxygen uptake (V̇O2 peak) was calculated and bivariate linear regression was 148 
used to estimate the treadmill speed necessary to elicit 60% of V̇O2 peak during exercise trials. 149 
 150 
In the 48 h before main trials, participants refrained from strenuous physical activity, alcohol 151 
and caffeine, and standardised their dietary intake using weighed records. On the evening 152 
before main trials, participants were provided with a standardised meal (3138 kJ; 71% 153 
carbohydrate, 18% fat, 11% protein) to consume before 21:00 after which only water was 154 
permitted until the start of the trials.  155 
 156 
Experimental trials 157 
Participants completed two experimental trials, control and exercise, in a counterbalanced 158 
order and separated by approximately one week. On the morning of each trial, participants 159 
arrived at the laboratory at 08:30, at which point an intravenous cannula (21 G; Venflon, 160 
Becton Dickinson, Sweden) was inserted into an antecubital vein. Trials were then initiated 161 
with a venous blood sample taken at ~09:00 (0 h) and additional samples were collected at 1, 162 
1.5, 2.75, 4 and 7 h. During exercise trials, participants completed a 60-min bout of 163 
moderate-intensity treadmill exercise (60% of V̇O2 peak) between 0 and 1 h, and then rested 164 
in the laboratory for the remainder of the trial (1-7 h). Heart rate (RS100, Polar, United 165 
Kingdom) and rate of perceived exertion (RPE) (Borg 1970) were recorded every 15 min 166 
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during exercise, and expired air was collected throughout for ongoing measurement of V̇O2 167 
and V̇CO2. If necessary, treadmill speed was adjusted to maintain the desired exercise 168 
intensity. Participants rested for the entirety of control trials and samples of expired air were 169 
collected between 0 and 1 h to quantify resting energy expenditure; allowing the calculation 170 
of net energy expenditure elicited by exercise. Participants were provided with a standardised 171 
breakfast (2690 kJ; 72% carbohydrate, 18% fat, 10% protein) and lunch (3138 kJ; 43% 172 
carbohydrate, 25% fat, 32% protein) at 1.5 and 4 h, respectively.  173 
  174 
Biochemical analyses 175 
Venous blood samples were collected into ice-cooled monovettes pre-treated with 176 
anticoagulant (Sarstedt, Leicester, UK). Monovettes were spun immediately in a refrigerated 177 
centrifuge (4 
o
C) for 10 min at 2383 x g and the plasma supernatant was removed and 178 
aliquoted for storage at -80 
o
C. At each time point, commercially available enzyme-linked 179 
immunosorbent assays were used to measure plasma concentrations of FGF21, follistatin, 180 
fetuin-A (R & D Systems, Oxford, UK), LECT2 (MBL International, Massachusetts, USA), 181 
insulin and glucagon (Mercodia, Uppsala, Sweden), whilst plasma concentrations of full-182 
length SeP were measured using a sol particle homogeneous immunoassay as previously 183 
reported (Saito et al. 2001, Tanaka et al. 2016). The mean within-batch co-efficient of 184 
variation (CV) for these assays was ≤ 5.5%. Circulating concentrations of NEFA, glucose, 185 
triacylglycerol (TAG), total cholesterol, liver aminotransferases (AST, ALT) and gamma-186 
glutamyl transpeptidase (GGT) were analysed by enzymatic colorimetric methods using a 187 
benchtop analyser (Pentra 400; HORIBA ABX Diagnostics, Montpellier, France; within 188 
batch CV ≤ 4.2%). All were measured at 0 h only with the exception of plasma NEFA, which 189 
was measured at each sample time point. Insulin resistance was assessed by HOMA-IR and 190 
Adipo-IR as previously described (Matthews et al. 1985, Gastaldelli et al. 2007). 191 
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 192 
Plasma volume was calculated in each whole blood sample using established equations (Dill 193 
and Costill 1974).
 
Circulating protein concentrations were corrected, as previously described 194 
(Sherk et al. 2013), when plasma volume deviated significantly from baseline. 195 
Statistical analyses 196 
Unless otherwise stated, data are presented as mean ± SD or SEM for participant 197 
characteristics and outcome variables, respectively. Statistical analyses were performed using 198 
commercially available software (SPSS version 23.0, SPSS Inc., United States). Where 199 
appropriate, data were log transformed to meet assumptions for parametric statistical testing. 200 
Two-tailed, independent samples t-tests were used to compare differences in participant 201 
characteristics, fasted plasma protein and metabolite concentrations, and characteristics of the 202 
exercise performed between normal weight and overweight/obese groups. When parametric 203 
assumptions were not met before or after log transformation, non-parametric Wilcoxon 204 
matched-pairs signed rank test was used. Relationships between fasted hepatokine 205 
concentrations and other participant characteristics were assessed using bivariate Pearson’s 206 
and Spearman’s correlation analyses as appropriate. Three-way, mixed-design analysis of 207 
variance (ANOVA), consisting of two within-participant factors (trial and sample time) and 208 
one between-participant factor (group), was used to assess hepatokine responses to exercise. 209 
After inspection of main effects, the three-way interaction between trial, time and group was 210 
used to assess whether hepatokine responses during and after exercise, when compared to the 211 
control trial, differed between normal weight and overweight/obese groups. When this was 212 
not significant, the two-way interaction between trial and time was used to investigate the 213 
hepatokine response to exercise in the two groups combined. Statistically significant two-way 214 
interactions were investigated further with two-tailed paired samples t-tests to identify the 215 
times at which circulating concentrations differed between control and exercise trials. Due to 216 
11 
 
the sample size in this study, no correction for multiple comparisons was applied.  To help 217 
clarity in graphical presentation, total area under the concentration-time curve (AUC) was 218 
also calculated for each experimental trial and these data were analysed statistically using 219 
two-way mixed design ANOVA. Probability (P-) values ≤ 0.05 were considered statistically 220 
significant.   221 
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Results 222 
Participant characteristics 223 
Descriptive characteristics of the normal weight and overweight/obese groups can be found in 224 
Table 1. By design, the overweight/obese group had higher BMI, body mass, body fat 225 
percentage and waist circumference, but age was similar between groups. There was no 226 
difference in absolute cardiorespiratory fitness between groups but relative fitness was 227 
greater in the normal weight individuals due to their lower body mass. Fasted plasma glucose, 228 
insulin and HOMA-IR were similar between groups, but fasted plasma lipids were greater in 229 
the overweight/obese individuals, whilst Adipo-IR tended to be higher. There were no 230 
significant differences in AST, ALT or GGT between groups (data not shown).  231 
 232 
Insert table 1 here 233 
 234 
Fasted plasma hepatokine concentrations and associations with metabolic variables 235 
The overweight/obese individuals had greater fasted plasma concentrations of LECT2 and 236 
FGF21, but fasted concentrations of follistatin, fetuin-A and SeP were similar between 237 
groups (Table 1). Fasted circulating LECT2 and FGF21 were positively correlated with each 238 
other (rho
2
 = 36.9%, P = 0.03), body mass, BMI, WC, body fat, NEFA, TAG, Adipo-IR and 239 
glucagon (r
2
 ≥ 19.4%, P ≤ 0.02 or rho2 ≥ 17.6%, P ≤ 0.05), and negatively with relative V̇O2 240 
peak (r
2
 ≥ 27.0%, P ≤ 0.01). FGF21 was also marginally positively correlated with fasted 241 
plasma glucose (r
2
 = 18.1%, P = 0.048), whilst LECT2 was strongly positively correlated 242 
with HOMA-IR (rho
2
 = 43.2%, P = 0.001). Significant negative correlations were found 243 
between fasted concentrations of follistatin and the AST:ALT ratio (r
2
 = 18.5%, P = 0.05), 244 
fetuin-A and age (rho
2
 = 25%, P = 0.02), and between fasted concentrations of SeP and ALT 245 
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(r
2
 = 19.4%, P = 0.04). Further details of all significant correlations can be found in 246 
supplementary material. 247 
 248 
Exercise characteristics 249 
Participants in the normal weight group exercised at a greater treadmill speed due to their 250 
higher relative cardiorespiratory fitness. However, the relative intensity of the exercise 251 
performed was similar between groups (Table 2). Consequently, given the higher energy cost 252 
of exercise in the overweight/obese group as a result of their higher body mass, the net 253 
energy expenditure during exercise trials was similar between groups (P = 0.98). During the 254 
exercise trials, there was a significant reduction in plasma volume immediately post-exercise 255 
irrespective of group (0 vs 1 h: 58.5 ± 0.7 vs. 53.7 ± 0.7%; P < 0.01), which returned to 256 
baseline by 1.5 h.  257 
 258 
Insert table 2 here 259 
 260 
Circulating hepatokine responses to exercise 261 
Plasma FGF21 concentrations were higher in the overweight/obese group, irrespective of trial 262 
or time (Figure 1a; P = 0.003), but there was no interaction between trial, time and group (P 263 
= 0.19). With groups combined, there was a significant two-way interaction between trial and 264 
time for circulating FGF21 (Figure 2a; P < 0.001), and post-hoc analyses revealed that 265 
circulating concentrations were significantly higher at 1, 1.5 and 4 h in the exercise trial, 266 
compared with control (all P ≤ 0.005). Accordingly, the total AUC for FGF21 was 267 
significantly greater in the overweight/obese compared with the normal weight individuals 268 
(Figure 1b; P = 0.003), and in the exercise versus the control trials (Figure 2b; P = 0.003). 269 
However, there was no interaction between group and trial (P = 0.65).  270 
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 271 
Circulating follistatin was lower in the overweight/obese versus the normal weight group 272 
(Figure 1c; P = 0.05), but the interaction between trial, time and group was not significant (P 273 
= 0.94). In the whole study population, there was a significant two-way interaction between 274 
trial and time for plasma follistatin (Figure 2c; P = 0.001). Post-hoc analyses identified 275 
significantly higher concentrations at 2.75, 4 and 7 h in the exercise trial (P ≤ 0.02). Similarly, 276 
the total AUC for follistatin was significantly lower in the overweight/obese group (Figure 1d; 277 
P = 0.05) and greater in the exercise trials (Figure 2d; P < 0.01), but there was no interaction 278 
between group and trial (P = 0.41).  279 
 280 
Circulating LECT2 was higher in the overweight/obese group versus the normal weight 281 
group, (Figure 1e; P = 0.009), but there was no interaction between trial, time and group (P = 282 
0.38). For plasma concentrations of LECT2, the two-way interaction between trial and time 283 
in the whole study population was also not significant (Figure 2e; P = 0.06). The total AUC 284 
analyses for LECT2 mirrored these results with a significantly greater AUC in the 285 
overweight/obese group (Figure 1f; P < 0.01), but no significant difference between the 286 
control and exercise trials (Figure 2f; P = 0.07) and no interaction between group and trial (P 287 
= 0.45). 288 
 289 
Circulating concentrations of fetuin-A and SeP were similar between groups (Figures 1g and 290 
1i; P ≥ 0.20) and there were no interactions between trial, time and group (P ≥ 0.07). 291 
Furthermore, with groups combined, there were no interactions between trial and time 292 
(Figures 2g and 2i; P ≥ 0.11). In accordance, the total AUC for fetuin-A (Figures 1h and 2h) 293 
and SeP (Figures 1j and 2j) were similar between groups and between trials, and there were 294 
no significant interactions (all P ≥ 0.17).  295 
15 
 
 296 
Insert figure 1 297 
 298 
Insert figure 2 299 
 300 
Circulating responses of NEFA, glucagon and insulin to exercise 301 
Despite differences in the fasted state, circulating concentrations of NEFA were similar 302 
between groups throughout experimental trials (P = 0.09), and there was no significant 303 
interaction between trial, time and group (P = 0.13). However, with groups combined there 304 
was a significant two-way interaction between trial and time (Figure 3a; P < 0.001) and post-305 
hoc analyses revealed significantly higher concentrations of NEFA in the exercise trial at 1, 306 
1.5, 2.75 and 7 h (P ≤ 0.04). 307 
 308 
Circulating concentrations of glucagon, insulin and glucagon to insulin ratio were also similar 309 
between groups (P ≥ 0.27), and the three-way interactions between trial, time and group were 310 
not significant for any of these outcomes (P ≥ 0.16). However, in the whole study population, 311 
there were significant two-way interactions between trial and time for all of glucagon, insulin 312 
and the glucagon to insulin ratio (Figure 3b-d; P ≤ 0.03). Post-hoc tests revealed the glucagon 313 
to insulin ratio was significantly greater at 1 and 1.5 h in the exercise trial when compared to 314 
the control trial (P ≤ 0.02). This was primarily driven by significantly higher concentrations 315 
of glucagon (P ≤ 0.01) and occurred despite significantly higher concentrations of insulin at 316 
1.5 h in the exercise trial (P = 0.02). Glucagon remained elevated in the exercise trial at 2.75 317 
h (P = 0.03) but the consequential increase in the glucagon to insulin ratio was not 318 
statistically significant (P = 0.08).  319 
 320 
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Insert figure 3  321 
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Discussion 322 
This study investigated the impact of adiposity and acute exercise on five candidate 323 
hepatokines which have been identified as novel circulating proteins linking the liver and 324 
peripheral metabolism. Our findings suggest that circulating levels of LECT2, FGF21 and 325 
follistatin are modulated by adiposity and are associated with various anthropometric 326 
measurements and biomarkers of metabolic health. Additionally, our findings show that 327 
circulating levels of FGF21 and follistatin are transiently elevated after a single bout of 328 
moderate-intensity exercise, and these responses are preserved in overweight/obese 329 
individuals. These responses may help mediate the favourable metabolic impact of exercise, 330 
but further research is needed to assess causality. 331 
 332 
Previous reports have shown increased LECT2 in obese individuals, with or without 333 
nonalcoholic fatty liver disease (NAFLD), in two large Japanese cohorts (Okumura et al. 334 
2013, Lan et al. 2014). The current study is the first, however, to show that LECT2 is 335 
elevated in European men that are overweight/obese and correlates with BMI in a population 336 
of normal weight, overweight and obese individuals. In mice, hepatic expression and 337 
circulating concentrations of LECT2 are negatively regulated by hepatic AMPK (Lan et al. 338 
2014). Furthermore, eight weeks of high-fat overfeeding increased circulating concentrations 339 
of LECT2, alongside increases in body mass (Lan et al. 2014). As such, circulating LECT2 340 
may be increased in overweight and obese individuals due to chronic reduction of hepatic 341 
AMPK activity resulting from sustained energy surplus. In agreement with previous studies 342 
(Okumura et al. 2013, Lan et al. 2014), we show significant associations between LECT2 and 343 
fasted plasma insulin and HOMA-IR, whilst we also report, for the first time, significant 344 
correlations between fasted concentrations of LECT2, NEFA and Adipo-IR. LECT2 has been 345 
shown to inhibit insulin signalling in C2C12 myotubes via activation of Jun NH2-terminal 346 
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kinase (JNK) (Lan et al. 2014) but its effects on other peripheral tissues, including hepatic 347 
and adipose tissues, warrant further investigation.  348 
 349 
Previous reports have shown that fasted concentrations of FGF21 are elevated in obese 350 
individuals with normal or dysregulated glucose metabolism (Zhang et al. 2008, Chen et al. 351 
2011). Our findings are in agreement with these studies and show that FGF21 is also 352 
increased in individuals that are overweight/obese. Hepatic expression and secretion of 353 
FGF21 is increased during periods of starvation via the activation of peroxisome proliferator-354 
activated receptor alpha (PPAR-α) by circulating NEFA (Badman et al. 2007). Plasma 355 
concentrations of NEFA are also increased with obesity (Boden 2008), offering a potential 356 
mechanism to explain the increased FGF21 concentrations seen in the present study. In 357 
support of this, we report elevated fasted concentrations of NEFA in the overweight/obese 358 
group and a strong positive correlation between circulating concentrations of FGF21 and 359 
NEFA. Alternatively, a state of ‘FGF21 resistance’ may also result in elevated concentrations 360 
of FGF21 group (Potthoff et al. 2012) but it was beyond the scope of this study to investigate 361 
this hypothesis. 362 
 363 
Despite no statistically significant difference in the fasted state, we showed lower 364 
concentrations of follistatin in the overweight/obese group throughout trial days. Our findings 365 
are consistent with previous data which identified lower follistatin levels in obese individuals 366 
with T2DM (Ueland et al. 2012), yet contrast those of Hansen et al. (2013) who identified 367 
higher follistatin in T2DM patients. The reasons for these discrepancies are not clear at this 368 
time and further work is therefore needed to more fully understand the metabolism of 369 
follistatin in health and disease.   370 
 371 
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We report no differences between groups in concentrations of fetuin-A or SeP either in the 372 
fasted state or throughout trial days. This may suggest that the development of metabolic 373 
complications, and not adiposity per se, may be required to disrupt fetuin-A and SeP 374 
metabolism. Previous research has found no independent effect of obesity on fetuin-A 375 
concentrations (Obuchi et al. 2014), whilst studies reporting differences in SeP have recruited 376 
individuals with NAFLD or dysregulated glucose metabolism (Yang et al. 2011, Choi et al. 377 
2013).  378 
 379 
In the current study we demonstrate that circulating concentrations of FGF21 are increased 380 
immediately after an acute 60-min bout of moderate-intensity aerobic exercise, peaking 30 381 
min after the cessation of exercise, and remaining elevated for up to 3 h. A similar, albeit 382 
delayed, increase in circulating follistatin also occurred. These findings support previous 383 
studies showing that FGF21 and follistatin are increased with acute aerobic exercise (Slusher 384 
et al. 2015, Hansen et al. 2016a, 2016b). FGF21 and follistatin production are positively 385 
regulated by the glucagon to insulin ratio (Hansen et al. 2016a, 2016b), whilst FGF21 may 386 
also be increased via activation of PPAR-α by circulating NEFA (Kim et al. 2013, Hansen et 387 
al. 2016a).
 
The systemic glucagon to insulin ratio and circulating NEFA were both elevated 388 
in response to exercise in the present study. FGF21 improves glucose metabolism in skeletal 389 
muscle, adipose tissue and the liver, whilst follistatin may promote pancreatic beta cell 390 
survival, reduce circulating glucagon and preserve skeletal muscle mass (Camporez et al. 391 
2013, Hansen et al. 2016b). Transient increases in the circulating levels of these hepatokines 392 
may represent potential mechanisms which contribute to the short-term improvements in 393 
glycaemic control after acute exercise (Sylow et al. 2017).
 
 394 
 395 
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In the current study the responses of circulating FGF21 and follistatin to exercise were 396 
similar in both normal weight and overweight/obese participants. It has been previously 397 
shown that the FGF21 and follistatin responses to acute exercise are blunted in individuals 398 
with T2DM, and this may be the result of differences in the exercise-induced changes in 399 
circulating NEFA and the glucagon to insulin ratio (Hansen et al. 2016a). Furthermore, the 400 
response of FGF21 to 30 min of exercise at 75% V̇O2 peak has been shown to be reduced in 401 
obese individuals compared with healthy, normal weight controls (Slusher et al. 2015). 402 
Notably, although the participants in the study by Slusher and colleagues (Slusher et al. 2015) 403 
were reportedly healthy, the obese group had a mean HOMA-IR of 4.36, which approaches 404 
the 5.13 threshold previously used to distinguish insulin resistant individuals (Wildman et al. 405 
2008). The participants in the current study were free from chronic disease and fasted plasma 406 
glucose, insulin and HOMA-IR suggested they were not insulin resistant. It could, therefore, 407 
be speculated that exercise-induced increases in circulating FGF21 and follistatin are 408 
maintained in overweight/obese individuals with preserved glycaemic control but not once a 409 
degree of insulin resistance has developed. Notably, the exercise-induced changes in NEFA 410 
and the glucagon to insulin ratio were no different between groups in the current study. This 411 
speculative hypothesis, however, should be tested further. 412 
 413 
The current study is the first to investigate the acute effects of aerobic exercise on fetuin-A, 414 
LECT2 and SeP, but these hepatokines were unaffected by exercise. Fetuin-A, LECT2 and 415 
SeP are all negatively regulated by hepatic AMPK (Jung et al. 2013, Lan et al. 2014, 416 
Trepanowski et al. 2014) which is activated by exercise in an intensity-dependent manner 417 
(Camacho et al. 2006). It may be that higher intensity exercise is required to acutely modulate 418 
fetuin-A, LECT2 or SeP (Trepanowski et al. 2014), or that repeated bouts of exercise are 419 
required to elicit benefits; as shown previously for fetuin-A (Malin et al. 2013, 2014). 420 
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 421 
This study is not without limitation. Most prominently, this trial was conducted using a 422 
relatively small sample of normal weight and overweight/obese men. Given the lack of prior 423 
evidence we were unable to determine a priori whether our sample size was sufficient for all 424 
of our outcomes. The novel data presented in this manuscript may, however, be utilised to 425 
inform power calculations for future studies, particularly those investigating the effects of 426 
acute exercise on LECT2, SeP and fetuin-A. Our results also cannot be generalised to 427 
individuals with chronic metabolic disease or women. Notably, we did not directly measure 428 
intrahepatic fat or insulin sensitivity in the current study. These are important considerations 429 
because the development of metabolic disease may influence hepatokine metabolism. 430 
Furthermore, the heightened propensity for fatty liver development in men, and the potential 431 
metabolic influence of sex hormones, underscores the necessity for additional research to be 432 
undertaken in women.  433 
 434 
In conclusion, this study has identified higher circulating concentrations of FGF21 and 435 
LECT2, and lower follistatin, in overweight/obese men when compared to normal weight 436 
individuals. Moreover, circulating FGF21 and follistatin are acutely increased after moderate-437 
intensity aerobic exercise, and this beneficial shift in hepatokine profile is similar in both 438 
groups. These data provide new information regarding the effect of adiposity on the 439 
metabolism of several novel hepatokines and supports evidence for a potential role of FGF21 440 
and follistatin in the metabolic response to exercise. Additional work is needed to better 441 
understand the interaction between these novel proteins, obesity and chronic disease; as well 442 
as to better define their interaction with exercise and other metabolic perturbations. 443 
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Tables 573 
Table 1 – Participant Characteristics 574 
 
Normal weight 
(n=11) 
Overweight/obese 
(n=11) 
Anthropometry       
BMI (kg•m-2) a 23.4 (1.6) 29.2 (4.5)‡ 
Age (years) 36 ± 15 45 ± 14 
Body weight (kg) 69.8 ± 1.5 92.3 ± 3.4‡ 
Body fat (%) 16.9 ± 3.6 26.4 ± 4.0‡ 
Waist circumference (cm) 81.6 ± 5.3 96.0 ± 7.8‡ 
Cardiorespiratory Fitness       
Absolute V̇O2 peak (L•min
-1
) 3.46 ± 0.74 3.21 ± 1.21 
Relative V̇O2 peak (mL•kg BW
-1•min-1) 50.1 ± 11.9 38.5 ± 9.7† 
Circulating Metabolic Risk Factors        
Total cholesterol (mmol•L-1) 4.12 ± 0.73 4.91 ± 0.89* 
TAG (mmol•L-1) 1.04 ± 0.15 1.82 ± 0.24† 
NEFA (mmol•L-1) 0.39 ± 0.18 0.58 ± 0.14† 
FPG (mmol•L-1) 4.9 ± 0.2 5.0 ± 0.3 
FPI (pmol•L-1) 30.0 ± 12.2 37.1 ± 19.3 
Insulin Sensitivity       
HOMA-IR 0.95 ± 0.39 1.21 ± 0.67 
Adipo-IR 12.57 ± 8.99 21.98 ± 13.01 
Hepatokines       
FGF21 (pg•mL-1) 83 ± 55 190 ± 74‡ 
Follistatin (pg•mL-1) 795 ± 257 670 ± 154 
LECT2 (ng•mL-1) 31 ± 10 48 ± 17† 
Fetuin-A (µg•mL-1) 541 ± 137 497 ± 99 
SeP (µg•mL-1) 3.01 ± 0.39 2.81 ± 0.30 
29 
 
BMI: Body mass index; V̇O2 peak: Peak oxygen uptake; TAG: Fasted triacylglycerol; NEFA: 575 
Fasted non-esterified fatty acids; FPG: Fasted plasma glucose; FPI: Fasted plasma insulin; 576 
HOMA-IR: Homeostatic model assessment of insulin resistance; Adipo-IR: Adipose tissue 577 
insulin resistance index; FGF21: Fibroblast growth factor 21; LECT2: Leukocyte cell-derived 578 
chemotaxin 2; SeP: Selenoprotein P. 
 a
 Heterogeneous variance between groups, non-579 
parametric analyses performed and data presented as median (interquartile range). All other 580 
data presented as mean ± SD. Symbols indicate statistically significant differences between 581 
groups (
*
 < 0.05; 
† ≤ 0.01; ‡ < 0.001). 582 
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Table 2 – Exercise Characteristics 583 
 
Normal weight 
(n=11) 
Overweight/obese 
(n=11) 
Treadmill speed (km•h-1) 7.6 ± 1.0 6.8 ± 1.0* 
V̇O2 elicited (%V̇O2 peak) 59.3 ± 2.8 57.9 ± 2.3 
Net energy expenditure (kJ) 2211 ± 507 2217 ± 509 
Heart rate (beats•min-1) 141 ± 29 139 ± 19 
Rate of perceived exertion (6-20) 13 ± 1 12 ± 1 
V̇O2: oxygen uptake; V̇O2 peak: peak oxygen uptake. Data presented as mean ± SD. 
*
indicates 584 
a statistically significant difference between groups (P < 0.05). 585 
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Figure captions 586 
Figure 1 – Hepatokine responses in normal weight and overweight/obese groups. 587 
Circulating plasma concentrations FGF21 (a-b), follistatin (c-d), LECT2 (e-f), fetuin-A (g-h) 588 
and SeP (i-j) during control and exercise trials in both normal weight and overweight/obese 589 
groups. Meals were provided at 1.5 and 4 h. Exercise was performed between 0 and 1 h in the 590 
exercise trial only. Data presented as mean ± SEM. AUC represents the total area under the 591 
concentration-time curve for the given experimental day. P-values denote significant main 592 
effect of group irrespective or time or trial. 593 
 594 
Figure 2 – Hepatokine exercise responses with groups combined to a single population. 595 
Circulating plasma concentrations FGF21 (a-b), follistatin (c-d), LECT2 (e-f), fetuin-A (g-h) 596 
and SeP (i-j) during control and exercise trials in the whole study population combined. 597 
Meals were provided at 1.5 and 4 h. Exercise was performed between 0 and 1 h in the 598 
exercise trial only. Data presented as mean ± SEM. AUC represents the total area under the 599 
concentration-time curve for the given experimental day. * indicates significant difference 600 
from control trial at the same time point (all P ≤ 0.02). P-values on AUC plots denote 601 
significant difference between control and exercise trials.  602 
 603 
Figure 3 – Responses in NEFA, glucagon and insulin with groups combined to a single 604 
population. Circulating plasma concentrations (a) NEFA (b) glucagon (c) insulin and (d) the 605 
glucagon to insulin ratio during control and exercise trials in the whole study population 606 
combined. Meals were provided at 1.5 and 4 h. Exercise was performed between 0 and 1 h in 607 
the exercise trial only. Data presented as mean ± SEM. * indicates significant difference from 608 
control trial at the same time point (all P ≤ 0.04).   609 
 610 
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